Citations

Clear

8 citation(s) found for "Tinsley, Sara".

Mindfulness‐Based Stress Reduction Effects on Chemotherapy‐Induced Peripheral Neuropathy Among Breast Cancer Survivors
Poudel, Ranjita , Tofthagen, Cindy S., Reich, Richard R. , Rodriquez, Carmen, Krothapalli, Mahathi, Tinsley‐Vance, Sara M., Park, Jong Y. , Meng, Hongdao, Lin, Katherine J., Chamkeri, Ramya, Nidamanur, Sreenidhi, Tofthagen, Cindy , Park, Jong Y , Tofthagen, Cindy S , Morgan, Sandra P. , Tinsley-Vance, Sara, Meng, Hongdao , Kip, Kevin E. , Lengacher, Cecile A.

Mayo Clinic

Psycho-Oncology | March 14, 2026 | Volume: 35 | Issue: 3 | Pages: No page available

10.1002/pon.70427 | PMID 41831208 Get It

ABSTRACT Background Chemotherapy‐induced peripheral neuropathy (CIPN), characterized by loss of sensation and impaired physical function, is a prevalent and debilitating side effect of chemotherapy, affecting 30%–50% of breast cancer survivors (BCS) with effects lasting years after treatment completion. Mindfulness‐based interventions are shown to be efficacious in reducing symptoms in neuropathies. This subgroup analysis examined the effect of Mindfulness‐Based Stress Reduction on Breast Cancer (MBSR(BC)) compared to Breast Cancer Education Support (BCES) or Usual Care (UC) on CIPN among BCS who received chemotherapy or chemotherapy and radiation. Methods BCS ( n = 114) were randomly assigned to the 6‐week MBSR(BC) ( n = 48), BCES ( n = 52), or UC ( n = 14) regimen. Demographic and clinical data were assessed at baseline, and CIPN was assessed using the Chemotherapy‐Induced Peripheral Neuropathy assessment tool (CIPNAT) at baseline, 6, 12, and 26 weeks. Between‐ and within‐group differences were evaluated and change over time was compared between groups. Results BCS (mean age = 52.7 years, range: 28–81 years) were primarily White and non‐Hispanic ( n = 78, 68%). The pattern of effect sizes was similar for CIPNAT symptoms and interference with improvements in CIPN for MBSR(BC) and BCES groups overtime. For both groups, the effects were larger compared to the UC. Differences tended to increase over time with significant effects observed between MBSR(BC) and UC, and between BCES and UC at weeks 12 and 26. Conclusions The findings indicate that MBSR(BC) and BCES may effectively reduce CIPN symptoms among BCS compared to UC. MBSR(BC) and BCES programs are effective non‐pharmacological interventions for CIPN that may translate into practice.
Cost‐Utility Analysis of a Group Mindfulness Program Compared to an Education Support Program for Breast Cancer Survivors With Cognitive Impairment: Evidence From a Randomized Controlled Trial
Tate, Rio , Park, Jong Y. , Hueluer, Gizem, Nguyen, Anh , Veal, Britney , Joshi, Anisha, Krothapalli, Mahathi, Nidamanur, Sreenidhi, Cox, Charles, Padgett, Lynne, Bornstein, Elizabeth, Lucas, Jean M., Fonseca, Tamela , Donovan, Kristine A. , Chamkeri, Ramya, Reich, Richard R. , Park, Jong Y , Veal, Britney , Fonseca, Tamela , Meng, Hongdao , Lengacher, Cecile A. , Rodriguez, Carmen S , Kip, Kevin E. , Morgan, Sandra P. , Tinsley, Sara , Cox, Charles E., Moscoso, Manolete S.

Mayo Clinic

Psycho-Oncology | July 23, 2025 | Volume: 34 | Issue: 7 | Pages: No page available

10.1002/pon.70220 | PMID 40696563 Get It

ABSTRACTObjectiveTo conduct an economic evaluation of a group mindfulness program compared to an education support program for breast cancer survivors (BCS).MethodsThe cost‐utility analysis (cost per quality‐adjusted life year [QALY]) was performed from a single‐center randomized controlled trial in the United States. Data from 181 BCS were included in the analysis (91 from the mindfulness‐based stress reduction for breast cancer, MBSR(BC) and 90 from the Breast Cancer Education Support, (BCES)). Analyses were conducted from two perspectives: societal and healthcare system. The EuroQol EQ‐5D‐5L was used to measure quality of life and the Client Service Receipt Inventory (CSRI) was used to measure health services utilization from baseline through 26 weeks. The impact of MBSR(BC) on health services utilization and costs was estimated with generalized linear models.ResultsIn the reference case analyses (societal perspective), the average total cost in the MBSR(BC) group was $5744 compared with $6140 in the BCES group. At the end of follow‐up, the MBSR(BC) group dominated BCES in terms of Incremental Cost Utility Ratio (ICUR), with MBSR(BC) providing an incremental cost of −$541 (95% CI: −$3400, $2318) and a 0.021 QALY (95% CI: −0.014, 0.055). Net monetary benefit (NMB) analysis showed that MBSR(BC) has a higher probability of achieving positive NMB across a range of possible societal willingness‐to‐pay for improving quality of life.ConclusionsOur findings suggest that MBSR(BC) is likely to be cost‐effective for breast cancer survivors over 6 months. Cost savings primarily resulted from reduced ER and hospital admissions and tests.
Advancing drug development in myelodysplastic syndromes
McGraw, Kathy L. , Cunningham, Lea, Kim, Nina , Jen, Emily Y. , Ehrlich, Lori A. , Aplan, Peter D. , Garcia‐Manero, Guillermo , Foran, James M. , Zeidan, Amer M., Scott, Bart L. , Buckstein, Rena , Tinsley-Vance, Sara, Verma, Amit , Wroblewski, Tanya, Pavletic, Steven Z. , Zeidan, Amer M. , Verma, Amit , Kim, Nina , Jen, Emily Y , Ehrlich, Lori A , Aplan, Peter D , Garcia, Jacqueline S , Komrokji, Rami S , Sekeres, Mikkael A , Scott, Bart , Verma, Amit , Zeidan, Amer M , Mina, Alain , Calvo, Katherine R. , Garcia, Jacqueline S. , Dezern, Amy Elizabeth , Komrokji, Rami S. , Sekeres, Mikkael A. , Norsworthy, Kelly J.

Mayo Clinic

Blood Advances | December 30, 2024 | Volume: 9 | Issue: 5 | Pages: 1095-1104

10.1182/bloodadvances.2024014865 | PMID 39786387 Get It

Abstract Myelodysplastic syndromes/neoplasms (MDSs) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the US Food and Drug Administration, (eg, luspatercept, ivosidenib, decitabine/cedazuridine, and imetelstat), there has been little progress in the development of truly transformative therapies for the treatment of patients with MDS. Challenges to advancing drug development in MDS are multifold but may be grouped into specific categories, including criteria for risk stratification and eligibility, response definitions, time-to-event end points, transfusion end points, functional assessments, and biomarker development. Strategies to address these challenges and optimize future clinical trial design for patients with MDS are presented here.
A Randomized Clinical Trial of Mindfulness-Based Stress Reduction Program Among Breast Cancer Survivors Post-Treatment: Evaluating Mediators of Cognitive Improvement
Hülür, Gizem , Wang, Julia R., Reich, Richard R. , Meng, Hongdao , Morgan, Sandra P. , Joshi, Anisha, Tinsley, Sara , Krothapalli, Mahathi, Nidamanur, Sreenidhi, Cox, Charles, Lucas, Jean M., Fonseca, Tamela , Bornstein, Elizabeth, Donovan, Kristine A. , Padgett, Lynne, Chamkeri, Ramya, Patel, Diya , Hornback, Estella, Hueluer, Gizem , Morgan, Sandra , Tinsley, Sara , Lengacher, Cecile A. , Park, Jong Y. , Kip, Kevin E. , Kiluk, John V. , Moscoso, Manolete S. , Rodríguez, Carmen C.S.

Mayo Clinic

Journal of Integrative and Complementary Medicine | December 23, 2024 | Volume: 31 | Issue: 4 | Pages: 367-377

10.1089/jicm.2024.0493 | PMID 39711191 Get It

Introduction: The Mindfulness-Based Stress Reduction program for breast cancer survivors (MBSR [BCs]) is a stress-reducing program designed to increase cognitive functioning through four meditational practices. This randomized clinical trial aimed to determine if improvements in cognitive functioning and perceived cognitive abilities achieved from the MBSR(BC) were mediated through increased mindfulness, decreased rumination, and decreased perceived stress. Methods: Breast cancer survivors (BCSs) who met inclusion criteria of stage I, II, or III BC and received either chemotherapy (CT) or both CT and radiation were randomized to either the 6-week MBSR(BC), or Breast Cancer Education Support (BCES) program, or to a usual care (UC) regimen. Analysis of covariance was first implemented to identify potential mediators, followed by a formal mediational analysis to evaluate the effects of MBSR(BC) on 6-, 12-, and 26-week outcomes. Results: After consent, 212 BCS were randomized to MBSR(BC) ( n = 91), BCES ( n = 90), or UC ( n = 31). The mean age was 56.5 and the majority of the BCS, 73.1%, were White and non-Hispanic. Results showed increases in “observing” as part of mindfulness as a potential mediator of MBSR(BC) effects on impairments on quality of life and logical memory at 6 months relative to UC. No mediation effects were identified for outcomes measured at 6 or 12 weeks and also when MBSR(BC) was compared with the BCES program. Discussion: These results partially supported our hypothesis that improvement in cognitive functioning would occur through increased mindfulness. Although few mediating relationships were identified, results showed a relationship between mindfulness and cognitive functioning. Both mediating relationships occurred through increases in “observing,” a subconcept of “mindfulness,” when compared to the MBSR(BC) with UC at 6 months. This study shows that mediators may help “optimize” clinical therapeutic treatment effects, thus contributing to the advancement of science. Trial Registration: ClinicalTrials.gov, www.ClinicalTrials.gov . Registration Number: NCT02786797.
The Moderating Role of Genetics on the Effectiveness of the Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) Program on Cognitive Impairment
Park, Jong Y. , Rodriguez, Carmen S., Meng, Hongdao , Morgan, Sandra P. , Joshi, Anisha, Hueluer, Gizem, Wang, Julia R., Tinsley, Sara , Cox, Charles, Donovan, Kristine A. , Bornstein, Elizabeth, Lucas, Jean M., Fonseca, Tamela , Krothapalli, Mahathi, Padgett, Lynne, Nidamanur, Sreenidhi, Hornback, Estella, Patel, Diya , Chamkeri, Ramya, Reich, Richard R. , Morgan, Sandra , Tinsley, Sara , Park, Jong Y , Lengacher, Cecile A. , Kip, Kevin E. , Kiluk, John V. , Moscoso, Manolete S.

Mayo Clinic

Biological Research For Nursing | October 17, 2024 | Volume: 27 | Issue: 2 | Pages: 216-228

10.1177/10998004241289629 | PMID 39413359 Get It

Background Genetics may influence symptoms experienced by breast cancer survivors (BCS) by moderating the effects of stress-reducing interventions, including the Mindfulness-Based Stress Reduction (MBSR(BC)) program, to reduce symptom severity. As part of a larger clinical trial, the aim of this study was to evaluate genetic variants as moderators of MBSR(BC) on improvements among BCS in cognitive functioning and symptoms. Methods BCS ( n = 128) were randomized to MBSR(BC) or the Breast Cancer Education Support Program. Objective neuropsychological and subjective measures of cognitive performance, and psychological and physical symptoms were collected at baseline, 6, 12, and 26 weeks. Linear mixed models were implemented to identify MBSR(BC)’s effects over time. A total of 22 single nucleotide polymorphisms (SNPs) from 20 genes known to be related to these symptoms were investigated using genomic DNA. These SNPs were tested as moderators of MBSR(BC) program effects. Results Results showed MBSR(BC) participants experienced significantly greater benefits in cognitive functioning, however, the level of benefit varied based on one’s genetic profile. Effects sizes, consistency across similar measures were investigated. Among 22 candidate SNPs, rs4680 in COMT, rs1800497 in ANKK1, and rs6277 in DRD2 demonstrated the strongest, most consistent positive effects in moderating MBSR(BC)’s impact on cognitive outcomes. Conclusions Although the effects were small, this translational research may potentially identify BCS with genotypes that would be most influenced by the MBSR(BC) program. These results may be used to develop personalized intervention programs tailored to the genetic profile of each breast cancer survivor who received chemotherapy or chemotherapy and radiation. Trial Registration ClinicalTrials.gov, https://www.ClinicalTrials.gov Registration Number: NCT02786797.
Efficacy of Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) a Treatment for Cancer-related Cognitive Impairment (CRCI): A Randomized Controlled Trial
Reich, Richard R. , Rodriguez, Carmen S., Nguyen, Anh , Meng, Hongdao , Tinsley, Sara , Hueluer, Gizem, Donovan, Kristine A. , Bornstein, Elizabeth, Nidamanur, Sreenidhi, Padgett, Lynne, Lucas, Jean M., Fonseca, Tamela , Joshi, Anisha, Lin, Katherine, Goodman, Matthew , Hülür, Gizem , Tinsley, Sara , Hueluer, Gizem , Lengacher, Cecile A. , Park, Jong Y. , Moscoso, Manolete S. , Kiluk, John V. , Kip, Kevin E.

Mayo Clinic

Journal of Integrative and Complementary Medicine | September 18, 2024 | Volume: 31 | Issue: 1 | Pages: 75-91

10.1089/jicm.2024.0184 | PMID 39291332 Get It

Introduction: The Mindfulness-Based Stress Reduction (MBSR) Program for breast cancer survivors (BCS) is designed to enhance cognitive training through formal and informal meditational practices. This randomized clinical trial (RCT) aimed to evaluate if BCS assigned to either the MBSR(BC), Breast Cancer Education Support (BCES), or Usual Care (UC) regimens experienced greater improvements at 6, 12, and 26 weeks on objective and subjective cognitive performance. Methods: BCS ( n = 212) randomized to a three-group RCT: MBSR(BC) ( n = 91), BCES ( n = 90), or UC ( n = 31) were assessed on cognitive performance and symptoms at baseline, 6, 12, and 26 weeks. Linear mixed models were fit to evaluate the effects of the MBSR(BC) program, hypothesizing ordered effect improvements: (MBSR[BC] highest, BCES intermediate, UC lowest) along with baseline characteristics evaluated as moderators. Results: Of the BCS (mean age of 57), 73% were White, and non-Hispanic, and 77% received both chemotherapy (CT) and radiation. Cognitive performance improved in all groups. Although there were no statistically significant between-group differences in cognitive outcomes, significant symptom reductions occurred for the MBSR(BC) group ( p = 0.003). Within-group effect size analysis at 26 weeks showed substantial improvements in all three groups (effect sizes >0.50) in subjective impairments and quality of life (effect size >0.50) and objective measures of cognitive performance. MBSR(BC) showed the largest within-group effect size in the reduction of fatigue (effect size = 0.81). Effect sizes occurred in the hypothesized direction for 10 of the 18 outcomes. Discussion: Although the MBSR(BC) program did not show significant differences in cognitive performance compared with BCES and UC, all groups improved and reductions in fatigue were beneficial for MBSR(BC). Results suggest that cognitive performance may improve after CT over time considering one’s natural history. Furthermore, BCS enrolled in RCTs may be more motivated to improve their health status (NCT02786797).
Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)
Ball, Somedeb , Travaglino, Erica , Ali, Najla H. Al, Fenaux, Pierre , Tinsley-Vance, Sara M., Schwabkey, Zaker , Brunner, Andrew M. , Bennett, John M. , Buckstein, Rena , Hasserjian, Robert P. , Odenike, Olatoyosi , Padron, Eric , Patnaik, Mrinal M. , Stahl, Maximilian , Xu, Mina L. , Sweet, Kendra , Sallman, David A. , Nimer, Stephen D. , Borate, Uma , Gore, Steven D. , Garcia‐Manero, Guillermo , Wang, Sa A. , Foucar, M K, Germing, Ulrich , Haferlach, Torsten , Miyazaki, Yasushi, Iastrebner, Marcelo , Cluzeau, Thomas , Loosdrecht, Arjan A. van de , Lanino, Luca , Bewersdorf, Jan Philipp , Marchetti, Monia , Maggioni, Giulia , Platzbecker, Uwe , Santini, Valeria , Díez‐Campelo, María , Singh, Avani , Jain, Akriti Gupta , Aguirre, Luis E. E. , Tinsley-Vance, Sara M., Chan, Onyee , Xie, Zhuoer , Kuykendall, Andrew , Bejar, Rafael , Carraway, Hetty E. , Dezern, Amy Elizabeth , Griffiths, Elizabeth A. , Halene, Stephanie , Lancet, Jeffrey E. , List, Alan F. , Loghavi, Sanam , Roboz, Gail J. , Sekeres, Mikkael A. , Steensma, David P. , Savona, Michael R. , Taylor, Justin , Hourigan, Christopher S. , Wei, Andrew H. , Sauta, Elisabetta , D'Amico, Saverio , Asti, Gianluca , Castellani, Gastone , Sanz, Guillermo , Efficace, Fabio , Kim, Tae Kon , Daver, Naval , Rozman, Marı́a , Órfão, Alberto , Scheinberg, Phillip , Miyazaki, Yasushi , Kulasekararaj, Austin , Kordasti, Shahram , Adès, Lionel , Zeidan, Amer M. , Komrokji, Rami S. , Della Porta, Matteo Giovanni

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 998-998

10.1182/blood-2023-186580 Get It

Background. The inclusion of gene mutations and chromosomal abnormalities in the 2022 WHO and ICC Classifications of MDS has enhanced diagnostic precision and is expected to improve clinical decision-making process. Although these two systems share similarities, clinically relevant discrepancies still exist and potentially cause inconsistency in their adoption in a clinical setting. In this study on behalf of the International Consortium for MDS (icMDS), we adopted a data-driven approach to provide a harmonization roadmap between the 2022 WHO and ICC classification for MDS. A modified Delphi Process consensus approach is currently ongoing among icMDS experts to finalize a harmonized MDS classification scheme. Methods. We analyzed retrospective international cohorts of patients with a diagnosis of MDS (n=7017) and AML (n=1002) according to WHO 2016 criteria. Hierarchical Dirichlet Processes were applied to define clusters capturing broad dependencies among all gene mutations and cytogenetic abnormalities. To investigate the features of importance and their impact on the clustering process, we employed the SHapley Additive exPlanations approach (SHAP). This allowed to define harmonized labels for each clinical entity. The clinical relevance of the unsupervised clustering was assessed through the analysis of phenotypic features and outcomes among each group. ( Blood 2022;140: 9828-9830) Results. Patients' characteristics are summarized in Table 1. We identified 9 clusters, defined by specific genomic features. The cluster of highest hierarchical importance was characterized by biallelic inactivation of TP53 (biTP53). According to SHAP analysis, bi TP53 was defined as 2 or more TP53 mutations, or 1 mutation with copy number loss or cnLOH. Most patients assigned to bi TP53 cluster had TP53 VAF>10% (77.9%) and complex karyotype (70.1%). Assignment to bi TP53 cluster was irrespective of blast count. Patients with monoallelic TP53 mutation segregated into other clusters. Hierarchically, the second cluster included patients with del(5q). SHAP analysis highlighted 5q deletion alone, or with one other chromosomal abnormality other than -7, and absence of bi TP53, as the most relevant features. Most of these patients had blast counts <5% (88.1%). The third distinct cluster included patients with SF3B1 mutations (in the absence of concurrent del(7q), abn3q26.2, complex karyotype or RUNX1 mutation). Most patients with MDS and SF3B1 mutation had <5% blasts (94.2%). Common co-mutated variants in the SF3B1 cluster included mutant DNMT3A (25.2%) and TET2 (38.3%). Morphologically defined MDS cases (i.e., not meeting criteria for bi TP53, del(5q) or SF3B1) were preferentially assigned to the following additional clusters: SF3B1 and concurrent higher-risk mutations (e.g., RUNX1 and ASXL1); SRSF2 and concomitant TET2 mutations; U2AF1 mutations with del(20q), del(7q) or -7; SRSF2 with TET2 mutations and co-mutational patterns including RUNX1 and ASXL1; and AML-like genomic signatures. Our analyses suggest that morphologically defined MDS is characterized by a large heterogeneity in terms of mutation profiles, not entirely captured by the presence of unilineage versus multilineage dysplasia, percentage of bone marrow blasts, and presence of hypocellularity and fibrosis. To better investigate the continuum between high risk MDS (i.e., patients with ≥10% blasts) and AML, an exploratory comparison was made using a cohort of AML (defined according to WHO 2016) patients analyzed using the same statistical methods. Only a partial overlap in genetic signatures was observed between MDS with ≥10% blasts and AML. However, similarities were observed between the AML-like MDS clusters (characterized by mutant NPM1, bZIP CEBPA, and Core Binding Factor abnormalities) and AML clusters defined by the same genetic signature, thus supporting the classification of these entities as AML, irrespective of blast count. Conclusion. Our study demonstrated the utility of a data-driven approach based on advanced statistical methods to generate a harmonized classification for MDS. Table 2 shows a provisional, hierarchical classification algorithm. Further refinement of entity labels and classification criteria is the subject of the ongoing modified Delphi Process consensus approach among icMDS experts.